Cambridge funding news: Health care and biotechnology top recent local investments – Yahoo News

Photo: Unsplash

Cambridge-based biopharma company Epizyme has secured $100 million in private equity funding, according to company database Crunchbase, topping the citys recent funding headlines. The cash infusion was announced Nov. 7 and financed by Royalty Pharma.

According to its Crunchbase profile, "Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors. Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future."

The 13-year-old company has raised five previous funding rounds, including a $10 million post IPO equity round in 2014.

The round brings total funding raised by Cambridge companies in health care over the past month to $391 million, an increase of $181 million from the month before. The local health care industry has seen 91 funding rounds over the past year, capturing a total of $3.4 billion in venture funding.

In other local funding news, biopharma company EGenesis announced a $100 million Series B funding round on Nov. 7, led by Fresenius Medical Care.

According to Crunchbase, "EGenesis designs xenotransplantation for the benefit of human health. Its technology helps transform xenotransplantation into a medical procedure, enabling clinical researchers to address the global organ shortage."

Founded in 2014, the company has raised two previous rounds, including a $38 million Series A round in 2017.

This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.

Read the original:
Cambridge funding news: Health care and biotechnology top recent local investments - Yahoo News

Global Biotechnology Market North America Is Expected To Account For Higher Market Share Of More Than 45% Driven By Increasing Investment In Us On…

Global Biotechnology Market is expected to grow at a CAGR of 14% to reach US$ 1,254.1 million in 2024. The growth is coupled with rising demand of modern and innovative technologies such as DNA sequencing, recombinant technology, fermentation, tissue engineering. Further, rising demand for food to meet the need of ever increasing population and scarce availability of non-renewable natural resources also expected to drive the biotechnology market. Application of Genetic engineering and Genetic Modification (GM) processes to agricultural food products also expected to drive the business growth. Furthermore, decreasing prices of DNA sequencing technologies will encourage R&D activities to better understand genetic variations and develop therapeutic solutions.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/10844

Moreover, development of novel techniques and their implementation by the organisation by collaborating with the other participants will drive the Global Biotechnology Market. Further, increasing demand for therapeutic and diagnostic solutions on principles of red biotechnology, DNA sequencing, and recombinant technology is expected to drive the Global Biotechnology Market through 2024. Increasing prevalence of diseases such as hepatitis B, cancer, and other orphan disorders is also expected to fuel demand in the forecast period.

In 2017, North America dominated the overall market. The market growth is driven by the increasing R&D investments relating to new drug discovery and development. U.S. held highest market in North America due to increasing level of per capita spending on healthcare than other countries and has a high growth rate amongst other countries. According to the estimates published by OECD Health Statistics in 2014, it has been estimated that in 2012, U.S. spent nearly 16.9% of its GDP towards healthcare expenditure, which is the highest. The fact supports the estimated share of Global Biotechnology Market.

Asia Pacific is expected to have higher growth rate in the forecast period owing to the presence of patient awareness, rapidly improving healthcare infrastructure, and rising healthcare expenditure levels in the emerging markets. Global Biotechnology Market include the developing economies of China and India.

In 2017, nanobiotechnology held the highest market share. The Global Biotechnology Market growth is driven by fermentation and cell-based assay segments owing to rising R&D initiatives by various biotechnological and pharmaceutical companies.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/10844

Global Biotechnology Market

Market Segmentation By Technologyo DNA Sequencingo Nanobiotechnologyo Tissue engineering and Regenerationo Fermentationo Cell Based Assayo PCR Technologyo Chromatography Marketo Others

By Applicationso Healtho Food & Agricultureo Natural Resources & Environmento Industrial Processingo Bioinformaticso Others

The above data will be provided for following regions/countries from 2013-2024 (USD Million)

North Americao U.S.o Canada

Europeo Germanyo UKo Franceo Spaino Italy

Asia Pacifico Chinao Indiao Japano Australia

Latin Americao Argentinao Brazilo Mexico

Middle East and Africao South Africao Saudi Arabia

MAJOR TOC OF THE REPORT

Chapter One: Biotechnology Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Biotechnology Market Competition, by Players

Chapter Four: Global Biotechnology Market Size by Regions

Chapter Five: North America Biotechnology Revenue by Countries

Chapter Six: Europe Biotechnology Revenue by Countries

Chapter Seven: Asia-Pacific Biotechnology Revenue by Countries

Chapter Eight: South America Biotechnology Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Biotechnology by Countries

Chapter Ten: Global Biotechnology Market Segment by Type

Chapter Eleven: Global Biotechnology Market Segment by Application

Chapter Twelve: Global Biotechnology Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Biotechnology Market Report at: https://www.maximizemarketresearch.com/market-report/global-biotechnology-market/10844/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read this article:
Global Biotechnology Market North America Is Expected To Account For Higher Market Share Of More Than 45% Driven By Increasing Investment In Us On...

Where Does ISEE Stock Rank in the Biotechnology Industry? – InvestorsObserver

IVERIC bio Inc (ISEE) is near the top in its industry group according to InvestorsObserver. ISEE gets an overall rating of 62. That means it scores higher than 62 percent of stocks. IVERIC bio Inc gets a 87 rank in the Biotechnology industry. Biotechnology is number 99 out of 148 industries.

Click Here to get the full Stock Score Report on IVERIC bio Inc (ISEE) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

IVERIC bio Inc (ISEE) stock is lower by -7.35% while the S&P 500 is up 0.32% as of 1:06 PM on Tuesday, Nov 12. ISEE is lower by -$0.25 from the previous closing price of $3.40 on volume of 899,010 shares. Over the past year the S&P 500 is up 13.60% while ISEE is up 45.83%. ISEE earned $1.70 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 1.85.

To see InvestorsObservers Sentiment Score for IVERIC bio Inc click here.

Read more:
Where Does ISEE Stock Rank in the Biotechnology Industry? - InvestorsObserver

Intrexon Corporation (XON) vs. MobileIron, Inc. (MOBL): Comparing the Biotechnology Industrys Most Active Stocks – E Globalist

Intrexon Corporation (NASDAQ:XON) shares are down more than -14.22% this year and recently increased 2.56% or $0.14 to settle at $5.61. MobileIron, Inc. (NASDAQ:MOBL), on the other hand, is up 5.01% year to date as of 11/14/2019. It currently trades at $4.82 and has returned -1.23% during the past week.

Intrexon Corporation (NASDAQ:XON) and MobileIron, Inc. (NASDAQ:MOBL) are the two most active stocks in the Biotechnology industry based on todays trading volumes. Investors are clearly interested in the two names, but is one a better choice than the other? We will compare the two companies across growth, profitability, risk, valuation, and insider trends to answer this question.

Companies that can consistently grow earnings at a high compound rate usually have the greatest potential to create value for shareholders in the long-run. Analysts expect XON to grow earnings at a 42.50% annual rate over the next 5 years.

A high growth rate isnt necessarily valuable to investors. In fact, companies that overinvest in low return projects just to achieve a high growth rate can actually destroy shareholder value. Profitability and returns are a measure of the quality of a companys business and its growth opportunities. Well use Return on Investment (ROI) to measure this. XONs ROI is -84.20% while MOBL has a ROI of -81.70%. The interpretation is that MOBLs business generates a higher return on investment than XONs.

If theres one thing investors care more about than earnings, its cash flow. XONs free cash flow (FCF) per share for the trailing twelve months was -0.31. Comparatively, MOBLs free cash flow per share was -0.06. On a percent-of-sales basis, XONs free cash flow was -0.03% while MOBL converted -0% of its revenues into cash flow. This means that, for a given level of sales, MOBL is able to generate more free cash flow for investors.

Liquidity and leverage ratios measure a companys ability to meet short-term obligations and longer-term debts. XON has a current ratio of 3.50 compared to 1.30 for MOBL. This means that XON can more easily cover its most immediate liabilities over the next twelve months. XONs debt-to-equity ratio is 0.92 versus a D/E of 0.00 for MOBL. XON is therefore the more solvent of the two companies, and has lower financial risk.

XON trades at a P/B of 3.08, and a P/S of 6.87, compared to a forward P/E of 166.21, a P/B of 13.39, and a P/S of 2.70 for MOBL. Given that earnings are what matter most to investors, analysts tend to place a greater weight on the P/E.

Analyst Price Targets and Opinions

Just because a stock is cheaper doesnt mean theres more value to be had. In order to assess value we need to compare the current price to where its likely to trade in the future. XON is currently priced at a -41.99% to its one-year price target of 9.67. Comparatively, MOBL is -33.97% relative to its price target of 7.30. This suggests that XON is the better investment over the next year.

Risk and Volatility

No discussion on value is complete without taking into account risk. Analysts use a stocks beta, which measures the volatility of a stock compared to the overall market, to measure systematic risk. A stock with a beta above 1 is more volatile than the market. Conversely, a beta below 1 implies a below average level of risk. XON has a beta of 2.25 and MOBLs beta is 1.60. MOBLs shares are therefore the less volatile of the two stocks.

Short interest is another tool that analysts use to gauge investor sentiment. It represents the percentage of a stocks tradable shares that are being shorted. XON has a short ratio of 33.75 compared to a short interest of 2.21 for MOBL. This implies that the market is currently less bearish on the outlook for MOBL.

MobileIron, Inc. (NASDAQ:MOBL) beats Intrexon Corporation (NASDAQ:XON) on a total of 8 of the 14 factors compared between the two stocks. MOBL is growing fastly, has higher cash flow per share, has a higher cash conversion rate and has lower financial risk. Finally, MOBL has better sentiment signals based on short interest.

Excerpt from:
Intrexon Corporation (XON) vs. MobileIron, Inc. (MOBL): Comparing the Biotechnology Industrys Most Active Stocks - E Globalist

3 Pick-and-Shovel Biotechnology Stocks — The Motley Fool

A low-risk way to play the biotech boom is to buy companies that are key suppliers to the industry. Companies like West Pharmaceutical Services (NYSE:WST), Veeva Systems (NYSE:VEEV), andRepligen (NASDAQ:RGEN) don't make headlines, but they all provide important products or services and have been wonderful long-term holdings.

In this episode of The Motley Fool's Industry Focus: Healthcare, host Shannon Jones and Fool.com contributor Brian Feroldi discuss each of these businesses in more detail and highlight why they can be great choices for biotech investors moving forward.

A full transcript follows the video.

This video was recorded on Jan. 23, 2019.

Shannon Jones: Let's talk about our third and final way to play it safe when it comes to biotechs, Brian, and that's with picks-and-shovels providers. Brian, what in the world is a pick and shovel?

Brian Feroldi: That's a that's a fun investor way of saying if you want to play a trend, one of the safer ways to do it is to buy the suppliers to that industry. Let me give you an example. There's a company called West Pharmaceutical Services. What they do is, they're a leading provider of components and systems that make drugs injectable. They provide vials, syringes, pens, stoppers, safety devices on the actual drugs themselves. If you have a thesis that the number of drugs that are available is going to grow and the number of people using them is going to grow, that naturally leads to more demand for the injectable products, the actual things that get the drug into your body -- the vials themselves, the packaging. All of those things are actually handled by West Pharmaceutical. These guys are one of the top-tier suppliers to the industry. In fact, about the top 75 biotech injectable products on the market actually come from West. This is a company that has no risk of any particular drug not going well. They're a steady-eddie business, and they've produced fantastic returns for shareholders over the last 10 years. They're actually up about 520%. That's a return that just smashes the index.

Jones: That's incredible returns for a company you don't hear a lot about. I did some research, this company has actually been around since the 1920s, which is very surprising to me. When you're in the position of being a biopharma company, you want that long-term expertise, that experience on the regulatory front, and even more so when it comes to the delivery components. Sometimes, getting that right -- both from a manufacturing and a compliance and regulatory perspective -- is just as important as getting the drug itself through to approval. So this company in particular, don't see it going away anytime soon. They supply pharmaceutical companies, they supply the biotech companies, even generic medical device companies, as well. They're massive. They've got over 50 locations, 28 facilities across the globe. This is one I'm certainly going to be watching, Brian.

Let's talk about the second picks-and-shovels play on your list, a company that I pretty much consider a good Fool favorite around here.

Feroldi: Veeva Systems should be a name that sounds familiar to a lot of longtime listeners. This a company that provides cloud-based software that's specifically made for the life sciences industry. Veeva Systems provides software that helps companies to manage their clinical trial data, manage customer relationships before and after the sale, can help with regulatory compliance. This is a company that has taken an extreme niche focus on the life science industry. Because of that, because of their tailored needs, they've really made a name for themselves. In fact, today, they currently boast more than 600 customers, which includes some of the biggest names in the industry, like GlaxoSmithKline, AstraZeneca, Biogen, Lilly, Novartis, etc. All of them rely on Veeva Systems' tools to help them with the clinical trial process.

Because of their niche focus, and because they've been able to grow so rapidly in the industry, this a company that's put up great returns for investors. They just IPO'd in 2014, so we don't have an incredible amount of data to look at, but investors who got in at the IPO are already up 177% because this company is growing so rapidly.

Jones: Another thing I love about the Veeva story is the CEO. He was actually a former executive from Salesforce. He recognized that for the pharmaceutical industry, they didn't have a cloud-based offering that could fit the needs of the industry itself. So there you have it, here comes Veeva. Veeva has a number of different products. In particular, they started off with a CRM, customer relationship management, tool built for big pharma specifically. But really, the big money maker has been Veeva Vault. That's helping companies manage all of the data that's needed to track and analyze clinical trials.

What I love about the Veeva platform is that with all these multiple products, they're all connected. As you're a biopharma company, you've got really high switching costs to come off of that one platform to go to another. I love the fact that they've got such a wide moat here. I think Veeva in and of itself is in a league of its own, and it's even expanding beyond biopharma. It's working now with companies in the consumer goods industry, manufacturing, even the chemical industry. Huge, huge growth ahead for Veeva.

Brian, let's turn our attention to the last picks-and-shovels play, one that I had not followed as much. But after doing some digging, this one certainly piqued my interest.

Feroldi: The final company today is called Repligen. Its ticker is RGEN. These guys make proteins and filtration technology that enable the drugs themselves to actually be manufactured. When you're making a drug, you need active ingredients. Repligen helps drug companies to actually make the equipment and provides the proteins that go into the drugs themselves.

These guys have literally a 95% market share in making proteins that are used to make vaccines and are used in gene therapy. They've grown right alongside with the general demand in the biotech market. In fact, this one of the best-performing stocks over the last decade. Their stock is up 1,320% over the last 10 years. Again, because they don't care specifically about any particular drug making it through, and because they're very well diversified among a lot of customers, they can ride the general wave of growth in biotech.

Jones: Absolutely. When you consider that the equipment that they make is needed to purify biologics, and just how crucial that is -- if you think about it, biologics themselves are products that are made from living cells. They're very large, very complex. After they're produced, though, you have to purify the product. This is really where Repligen stands out in terms of lowering the cost. Purification in and of itself is a very cost-intensive step, and one of the riskiest, too, when it comes to biologics manufacturing.

Speaking of biologics, there are currently over 1,000 biologics being studied for development. The growth runway on this stock is tremendous. That's across the globe. Also, interestingly enough, oncology is actually the leading therapeutic area with the maximum number of biologics under development right now. A lot to watch here on this particular company, especially as biologics are expected to hit over $300 billion by next year. It's a massive market.

All in all, Repligen is a great way for investors to ride the wave safely when it comes to biologics development, both on the development front and post-commercialization.

See the original post here:
3 Pick-and-Shovel Biotechnology Stocks -- The Motley Fool

Welcome to the SBC – Seed Biotechnology Center

The mission of the Seed Biotechnology Center (SBC)is to mobilize the research, educational and outreach resources of UC Davis in partnership with the seed and biotechnology industries to facilitate discovery and commercialization of new seed technologies for agricultural and consumer benefit.

A team of researchers including SBC Director of Research, Dr. Allen Van Deynze and Cristobal Heitmann, discover an indigenous variety of corn that can fix nitrogen from the atmosphere, instead of requiring synthetic fertilizers. Cristobal Heitman, Cris, was a beloved member of the UC Davis Plant Sciences Department. Criss energy and enthusiasm were a major catalyst in this research. Read more.

Plant Breeding Academy Addresses Global Food Needs

UC Davis' Department of Plant Sciences shares how PBA is changing the global food supply one scientist at a time.Read article.

A DryCardis the latest technology to improve the shelf-life of seeds. Dr. Kent Bradford, SBCDirector, describes how the amazingDryCard works. Read more.

Comstock Magazine highlighted the value of locating Sakatas Woodland Innovation Center in the Sacramento Valley. The regions fertile soil and ideal climate make it one of the best places in the world for seed production. In addition, its close proximity to UC Davis will allow Sakata to strengthen its already existing ties to the university. Learn more.

Scientists could engineer a spicy tomato. Is it worth it?

Scientists are working on growing a spicy tomato. Dr. Allen Van Deyneze, SBC Director of Research shares his insight on the research. Read article.

Benson Hill Teams Up with The African Orphan Crops Consortium to Combat Malnutrition Through Underutilized Crops

Allen Van Deynze, Director of Research, Seed Biotechnology Center, University of California, Davis and Scientific Director of the African Orphan Crops Consortium highlights effort to accelerate the ability of African scientists to develop better seeds and improve the diets of Africas children. Learn more

Read more here:
Welcome to the SBC - Seed Biotechnology Center

Is There Now An Opportunity In Cellect Biotechnology Ltd (APOP)? – Simply Wall St

Cellect Biotechnology Ltd (NASDAQ:APOP), a pharmaceuticals, biotechnology and life sciences company based in Israel, saw a significant share price rise of over 20% in the past couple of months on the NasdaqCM. As a small cap stock, hardly covered by any analysts, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value. Is there still an opportunity here to buy? Today I will analyse the most recent data on APOPs outlook and valuation to see if the opportunity still exists. Check out our latest analysis for Cellect Biotechnology

Are you a shareholder? If you believe APOP should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. Given the uncertainty from negative growth in the future, this could be the right time to de-risk your portfolio. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If youve been keeping an eye on APOP for a while, now may not be the best time to enter into the stock. Price climbed passed its industry peers, in addition to a risky future outlook. However, there are also other important factors which we havent considered today, such as the financial strength of the company. Should the price fall in the future, will you be well-informed enough to buy?

Price is just the tip of the iceberg. Dig deeper into what truly matters the fundamentals before you make a decision on Cellect Biotechnology. You can find everything you need to know about APOP in the latest infographic research report. If you are no longer interested in Cellect Biotechnology, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

Originally posted here:
Is There Now An Opportunity In Cellect Biotechnology Ltd (APOP)? - Simply Wall St

Global catastrophic risk – Wikipedia

A global catastrophic risk is a hypothetical future event which could damage human well-being on a global scale,[2] even crippling or destroying modern civilization.[3] An event that could cause human extinction or permanently and drastically curtail humanity's potential is known as an existential risk.[4]

Potential global catastrophic risks include anthropogenic risks (technology, governance) and natural or external risks.[3] Examples of technology risks are hostile artificial intelligence and destructive biotechnology or nanotechnology. Insufficient or malign global governance creates risks in the social and political domain, such as a global war, including nuclear holocaust, bioterrorism using genetically modified organisms, cyberterrorism destroying critical infrastructure like the electrical grid; or the failure to manage a natural pandemic. Problems and risks in the domain of earth system governance include global warming, environmental degradation, including extinction of species, famine as a result of non-equitable resource distribution, human overpopulation, crop failures and non-sustainable agriculture. Examples of non-anthropogenic risks are an asteroid impact event, a supervolcanic eruption, a lethal gamma-ray burst, a geomagnetic storm destroying electronic equipment, natural long-term climate change, or hostile extraterrestrial life.

Philosopher Nick Bostrom classifies risks according to their scope and intensity.[5] A "global catastrophic risk" is any risk that is at least "global" in scope, and is not subjectively "imperceptible" in intensity. Those that are at least "trans-generational" (affecting all future generations) in scope and "terminal"[clarification needed] in intensity are classified as existential risks. While a global catastrophic risk may kill the vast majority of life on earth, humanity could still potentially recover. An existential risk, on the other hand, is one that either destroys humanity (and, presumably, all but the most rudimentary species of non-human lifeforms and/or plant life) entirely or at least prevents any chance of civilization recovering. Bostrom considers existential risks to be far more significant.[6]

Similarly, in Catastrophe: Risk and Response, Richard Posner singles out and groups together events that bring about "utter overthrow or ruin" on a global, rather than a "local or regional" scale. Posner singles out such events as worthy of special attention on cost-benefit grounds because they could directly or indirectly jeopardize the survival of the human race as a whole.[7] Posner's events include meteor impacts, runaway global warming, grey goo, bioterrorism, and particle accelerator accidents.

Researchers experience difficulty in studying near human extinction directly, since humanity has never been destroyed before.[8] While this does not mean that it will not be in the future, it does make modelling existential risks difficult, due in part to survivorship bias.

Bostrom identifies four types of existential risk. "Bangs" are sudden catastrophes, which may be accidental or deliberate. He thinks the most likely sources of bangs are malicious use of nanotechnology, nuclear war, and the possibility that the universe is a simulation that will end. "Crunches" are scenarios in which humanity survives but civilization is irreversibly destroyed. The most likely causes of this, he believes, are exhaustion of natural resources, a stable global government that prevents technological progress, or dysgenic pressures that lower average intelligence. "Shrieks" are undesirable futures. For example, if a single mind enhances its powers by merging with a computer, it could dominate human civilization. Bostrom believes that this scenario is most likely, followed by flawed superintelligence and a repressive totalitarian regime. "Whimpers" are the gradual decline of human civilization or current values. He thinks the most likely cause would be evolution changing moral preference, followed by extraterrestrial invasion.[4]

Some risks, such as that from asteroid impact, with a one-in-a-million chance of causing humanity's extinction in the next century,[9] have had their probabilities predicted using straightforward, well-understood, and (in principle) precise methods (although even in cases like these, the exact rate of large impacts is contested).[10] Similarly, the frequency of volcanic eruptions of sufficient magnitude to cause catastrophic climate change, similar to the Toba Eruption, which may have almost caused the extinction of the human race,[11] has been estimated at about 1 in every 50,000 years.[12]

The relative danger posed by other threats is much more difficult to calculate. In 2008, an informal survey of small but illustrious group of experts on different global catastrophic risks at the Global Catastrophic Risk Conference at the University of Oxford suggested a 19% chance of human extinction by the year 2100. The conference report cautions that the results should be taken "with a grain of salt".[13] In November 2017, a statement by 15,364 scientists from 184 countries indicated that increasing levels of greenhouse gases from use of fossil fuels, human population growth, deforestation, and overuse of land for agricultural production, particularly by farming ruminants for meat consumption, are trending in ways that forecast an increase in human misery over coming decades.[3]

The 2016 annual report by the Global Challenges Foundation estimates that an average American is more than five times more likely to die during a human-extinction event than in a car crash.[14][15]

There are significant methodological challenges in estimating these risks with precision. Most attention has been given to risks to human civilization over the next 100 years, but forecasting for this length of time is difficult. The types of threats posed by nature may prove relatively constant, though new risks could be discovered. Anthropogenic threats, however, are likely to change dramatically with the development of new technology; while volcanoes have been a threat throughout history, nuclear weapons have only been an issue since the 20th century. Historically, the ability of experts to predict the future over these timescales has proved very limited. Man-made threats such as nuclear war or nanotechnology are harder to predict than natural threats, due to the inherent methodological difficulties in the social sciences. In general, it is hard to estimate the magnitude of the risk from this or other dangers, especially as both international relations and technology can change rapidly.

Existential risks pose unique challenges to prediction, even more than other long-term events, because of observation selection effects. Unlike with most events, the failure of a complete extinction event to occur in the past is not evidence against their likelihood in the future, because every world that has experienced such an extinction event has no observers, so regardless of their frequency, no civilization observes existential risks in its history.[8] These anthropic issues can be avoided by looking at evidence that does not have such selection effects, such as asteroid impact craters on the Moon, or directly evaluating the likely impact of new technology.[5]

Some scholars have strongly favored reducing existential risk on the grounds that it greatly benefits future generations. Derek Parfit argues that extinction would be a great loss because our descendants could potentially survive for four billion years before the expansion of the Sun makes the Earth uninhabitable.[16][17] Nick Bostrom argues that there is even greater potential in colonizing space. If future humans colonize space, they may be able to support a very large number of people on other planets, potentially lasting for trillions of years.[6] Therefore, reducing existential risk by even a small amount would have a very significant impact on the expected number of people who will exist in the future.

Exponential discounting might make these future benefits much less significant. However, Gaverick Matheny has argued that such discounting is inappropriate when assessing the value of existential risk reduction.[9]

Some economists have discussed the importance of global catastrophic risks, though not existential risks. Martin Weitzman argues that most of the expected economic damage from climate change may come from the small chance that warming greatly exceeds the mid-range expectations, resulting in catastrophic damage.[18] Richard Posner has argued that we are doing far too little, in general, about small, hard-to-estimate risks of large-scale catastrophes.[19]

Numerous cognitive biases can influence people's judgment of the importance of existential risks, including scope insensitivity, hyperbolic discounting, availability heuristic, the conjunction fallacy, the affect heuristic, and the overconfidence effect.[20]

Scope insensitivity influences how bad people consider the extinction of the human race to be. For example, when people are motivated to donate money to altruistic causes, the quantity they are willing to give does not increase linearly with the magnitude of the issue: people are roughly as concerned about 200,000 birds getting stuck in oil as they are about 2,000.[21] Similarly, people are often more concerned about threats to individuals than to larger groups.[20]

There are economic reasons that can explain why so little effort is going into existential risk reduction. It is a global good, so even if a large nation decreases it, that nation will only enjoy a small fraction of the benefit of doing so. Furthermore, the vast majority of the benefits may be enjoyed by far future generations, and though these quadrillions of future people would in theory perhaps be willing to pay massive sums for existential risk reduction, no mechanism for such a transaction exists.[5]

Some sources of catastrophic risk are natural, such as meteor impacts or supervolcanos. Some of these have caused mass extinctions in the past.

On the other hand, some risks are man-made, such as global warming,[22] environmental degradation, engineered pandemics and nuclear war. According to the Future of Humanity Institute, human extinction is more likely to result from anthropogenic causes than natural causes.[5][23]

In 2012, Cambridge University created The Cambridge Project for Existential Risk which examines threats to humankind caused by developing technologies.[24] The stated aim is to establish within the University a multidisciplinary research centre, Centre for the Study of Existential Risk, dedicated to the scientific study and mitigation of existential risks of this kind.[24]

The Cambridge Project states that the "greatest threats" to the human species are man-made; they are artificial intelligence, global warming, nuclear war, and rogue biotechnology.[25]

It has been suggested that learning computers that rapidly become superintelligent may take unforeseen actions or that robots would out-compete humanity (one technological singularity scenario).[26] Because of its exceptional scheduling and organizational capability and the range of novel technologies it could develop, it is possible that the first Earth superintelligence to emerge could rapidly become matchless and unrivaled: conceivably it would be able to bring about almost any possible outcome, and be able to foil virtually any attempt that threatened to prevent it achieving its objectives.[27] It could eliminate, wiping out if it chose, any other challenging rival intellects; alternatively it might manipulate or persuade them to change their behavior towards its own interests, or it may merely obstruct their attempts at interference.[27] In Bostrom's book, Superintelligence: Paths, Dangers, Strategies, he defines this as the control problem.[28]

Vernor Vinge has suggested that a moment may come when computers and robots are smarter than humans. He calls this "the Singularity."[29] He suggests that it may be somewhat or possibly very dangerous for humans.[30] This is discussed by a philosophy called Singularitarianism.

Physicist Stephen Hawking, Microsoft founder Bill Gates and SpaceX founder Elon Musk have expressed concerns about the possibility that AI could evolve to the point that humans could not control it, with Hawking theorizing that this could "spell the end of the human race".[31] In 2009, experts attended a conference hosted by the Association for the Advancement of Artificial Intelligence (AAAI) to discuss whether computers and robots might be able to acquire any sort of autonomy, and how much these abilities might pose a threat or hazard. They noted that some robots have acquired various forms of semi-autonomy, including being able to find power sources on their own and being able to independently choose targets to attack with weapons. They also noted that some computer viruses can evade elimination and have achieved "cockroach intelligence." They noted that self-awareness as depicted in science-fiction is probably unlikely, but that there were other potential hazards and pitfalls.[29] Various media sources and scientific groups have noted separate trends in differing areas which might together result in greater robotic functionalities and autonomy, and which pose some inherent concerns.[32][33] Eliezer Yudkowsky believes that risks from artificial intelligence are harder to predict than any other known risks. He also argues that research into artificial intelligence is biased by anthropomorphism. Since people base their judgments of artificial intelligence on their own experience, he claims that they underestimate the potential power of AI. He distinguishes between risks due to technical failure of AI, which means that flawed algorithms prevent the AI from carrying out its intended goals, and philosophical failure, which means that the AI is programmed to realize a flawed ideology.[34]

Biotechnology can pose a global catastrophic risk in the form of bioengineered organisms (viruses, bacteria, fungi, plants or animals). In many cases the organism will be a pathogen of humans, livestock, crops or other organisms we depend upon (e.g. pollinators or gut bacteria). However, any organism able to catastrophically disrupt ecosystem functions, e.g. highly competitive weeds, outcompeting essential crops, poses a biotechnology risk.

A biotechnology catastrophe may be caused by accidentally releasing a genetically engineered organism escaping from controlled environments, by the planned release of such an organism which then turns out to have unforeseen and catastrophic interactions with essential natural or agro-ecosystems, or by intentional usage of biological agents in biological warfare, bioterrorism attacks.[35] Terrorist applications of biotechnology have historically been infrequent.[35] To what extent this is due to a lack of capabilities or motivation is not resolved.[35]

Exponential growth has been observed in the biotechnology sector and Noun and Chyba predict that this will lead to major increases in biotechnological capabilities in the coming decades.[35] They argue that risks from biological warfare and bioterrorism are distinct from nuclear and chemical threats because biological pathogens are easier to mass-produce and their production is hard to control (especially as the technological capabilities are becoming available even to individual users).[35]

Given current development, more risk from novel, engineered pathogens is to be expected in the future.[35] Pathogens may be intentionally or unintentionally genetically modified to change virulence and other characteristics.[35] For example, a group of Australian researchers unintentionally changed characteristics of the mousepox virus while trying to develop a virus to sterilize rodents.[35] The modified virus became highly lethal even in vaccinated and naturally resistant mice.[36][37] The technological means to genetically modify virus characteristics are likely to become more widely available in the future if not properly regulated.[35]

Noun and Chyba propose three categories of measures to reduce risks from biotechnology and natural pandemics: Regulation or prevention of potentially dangerous research, improved recognition of outbreaks and developing facilities to mitigate disease outbreaks (e.g. better and/or more widely distributed vaccines).[35]

(See also Natural pathogens below.)

Cyberattacks have the potential to destroy everything from personal data to electric grids. Christine Peterson, co-founder and past president of the Foresight Institute, believes a cyberattack on electric grids has the potential to be a catastrophic risk.[38] Peterson also identifies attacks on Internet of Things devices as potentially catastrophic.

Global warming refers to the warming caused by human technology since the 19th century or earlier. Global warming reflects abnormal variations to the expected climate within the Earth's atmosphere and subsequent effects on other parts of the Earth. Projections of future climate change suggest further global warming, sea level rise, and an increase in the frequency and severity of some extreme weather events and weather-related disasters. Effects of global warming include loss of biodiversity, stresses to existing food-producing systems, increased spread of known infectious diseases such as malaria, and rapid mutation of microorganisms.

It has been suggested that runaway global warming (runaway climate change) might cause Earth to become searingly hot like Venus. In less extreme scenarios, it could cause the end of civilization as we know it.[39]

An environmental or ecological disaster, such as world crop failure and collapse of ecosystem services, could be induced by the present trends of overpopulation, economic development,[40] and non-sustainable agriculture. An October 2017 report published in The Lancet stated that toxic air, water, soils, and workplaces were collectively responsible for 9 million deaths worldwide in 2015, particularly from air pollution which was linked to deaths by increasing susceptibility to non-infectious diseases, such as heart disease, stroke, and lung cancer.[41] The report warned that the pollution crisis was exceeding "the envelope on the amount of pollution the Earth can carry" and threatens the continuing survival of human societies.[41]

Most environmental scenarios involve one or more of the following: Holocene extinction event,[42] scarcity of water that could lead to approximately one half of the Earth's population being without safe drinking water, pollinator decline, overfishing, massive deforestation, desertification, climate change, or massive water pollution episodes. Detected in the early 21st century, a threat in this direction is colony collapse disorder,[43] a phenomenon that might foreshadow the imminent extinction[44] of the Western honeybee. As the bee plays a vital role in pollination, its extinction would severely disrupt the food chain.

Romanian American economist Nicholas Georgescu-Roegen, a progenitor in economics and the paradigm founder of ecological economics, has argued that the carrying capacity of Earth that is, Earth's capacity to sustain human populations and consumption levels is bound to decrease sometime in the future as Earth's finite stock of mineral resources is presently being extracted and put to use; and consequently, that the world economy as a whole is heading towards an inevitable future collapse, leading to the demise of human civilization itself.[45]:303f Ecological economist and steady-state theorist Herman Daly, a student of Georgescu-Roegen, has propounded the same argument by asserting that "... all we can do is to avoid wasting the limited capacity of creation to support present and future life [on Earth]."[46]:370

Ever since Georgescu-Roegen and Daly published these views, various scholars in the field have been discussing the existential impossibility of distributing Earth's finite stock of mineral resources evenly among an unknown number of present and future generations. This number of generations is likely to remain unknown to us, as there is little way of knowing in advance if or when mankind will eventually face extinction. In effect, any conceivable intertemporal distribution of the stock will inevitably end up with universal economic decline at some future point.[47]:253256 [48]:165 [49]:168171 [50]:150153 [51]:106109 [52]:546549 [53]:142145

Nick Bostrom suggested that in the pursuit of knowledge, humanity might inadvertently create a device that could destroy Earth and the Solar System.[54] Investigations in nuclear and high-energy physics could create unusual conditions with catastrophic consequences. For example, scientists worried that the first nuclear test might ignite the atmosphere.[55][56] More recently, others worried that the RHIC[57] or the Large Hadron Collider might start a chain-reaction global disaster involving black holes, strangelets, or false vacuum states. These particular concerns have been refuted,[58][59][60][61] but the general concern remains.

Biotechnology could lead to the creation of a pandemic, chemical warfare could be taken to an extreme, nanotechnology could lead to grey goo in which out-of-control self-replicating robots consume all living matter on earth while building more of themselvesin both cases, either deliberately or by accident.[62]

Many nanoscale technologies are in development or currently in use.[63] The only one that appears to pose a significant global catastrophic risk is molecular manufacturing, a technique that would make it possible to build complex structures at atomic precision.[64] Molecular manufacturing requires significant advances in nanotechnology, but once achieved could produce highly advanced products at low costs and in large quantities in nanofactories of desktop proportions.[63][64] When nanofactories gain the ability to produce other nanofactories, production may only be limited by relatively abundant factors such as input materials, energy and software.[63]

Molecular manufacturing could be used to cheaply produce, among many other products, highly advanced, durable weapons.[63] Being equipped with compact computers and motors these could be increasingly autonomous and have a large range of capabilities.[63]

Phoenix and Treder classify catastrophic risks posed by nanotechnology into three categories:

At the same time, nanotechnology may be used to alleviate several other global catastrophic risks.[63]

Several researchers state that the bulk of risk from nanotechnology comes from the potential to lead to war, arms races and destructive global government.[36][63][65] Several reasons have been suggested why the availability of nanotech weaponry may with significant likelihood lead to unstable arms races (compared to e.g. nuclear arms races):

Since self-regulation by all state and non-state actors seems hard to achieve,[67] measures to mitigate war-related risks have mainly been proposed in the area of international cooperation.[63][68] International infrastructure may be expanded giving more sovereignty to the international level. This could help coordinate efforts for arms control. International institutions dedicated specifically to nanotechnology (perhaps analogously to the International Atomic Energy Agency IAEA) or general arms control may also be designed.[68] One may also jointly make differential technological progress on defensive technologies, a policy that players should usually favour.[63] The Center for Responsible Nanotechnology also suggests some technical restrictions.[69] Improved transparency regarding technological capabilities may be another important facilitator for arms-control.

A grey goo is another catastrophic scenario, which was proposed by Eric Drexler in his 1986 book Engines of Creation[70] and has been a theme in mainstream media and fiction.[71][72] This scenario involves tiny self-replicating robots that consume the entire biosphere using it as a source of energy and building blocks. Nowadays, however, nanotech expertsincluding Drexlerdiscredit the scenario. According to Chris Phoenix a "so-called grey goo could only be the product of a deliberate and difficult engineering process, not an accident".[73]

The scenarios that have been explored most frequently are nuclear warfare and doomsday devices. Although the probability of a nuclear war per year is slim, Professor Martin Hellman has described it as inevitable in the long run; unless the probability approaches zero, inevitably there will come a day when civilization's luck runs out.[74] During the Cuban missile crisis, U.S. president John F. Kennedy estimated the odds of nuclear war at "somewhere between one out of three and even".[75] The United States and Russia have a combined arsenal of 14,700 nuclear weapons,[76] and there is an estimated total of 15,700 nuclear weapons in existence worldwide.[76]

While popular perception sometimes takes nuclear war as "the end of the world", experts assign low probability to human extinction from nuclear war.[77][78] In 1982, Brian Martin estimated that a USSoviet nuclear exchange might kill 400450 million directly, mostly in the United States, Europe and Russia, and maybe several hundred million more through follow-up consequences in those same areas.[77]

Nuclear war could yield unprecedented human death tolls and habitat destruction. Detonating large numbers of nuclear weapons would have an immediate, short term and long-term effects on the climate, causing cold weather and reduced sunlight and photosynthesis[79] that may generate significant upheaval in advanced civilizations.[80]

Beyond nuclear, other threats to humanity include biological warfare (BW) and bioterrorism. By contrast, chemical warfare, while able to create multiple local catastrophes, is unlikely to create a global one.

The 20th century saw a rapid increase in human population due to medical developments and massive increases in agricultural productivity[81] such as the Green Revolution.[82] Between 1950 and 1984, as the Green Revolution transformed agriculture around the globe, world grain production increased by 250%. The Green Revolution in agriculture helped food production to keep pace with worldwide population growth or actually enabled population growth. The energy for the Green Revolution was provided by fossil fuels in the form of fertilizers (natural gas), pesticides (oil), and hydrocarbon-fueled irrigation.[83] David Pimentel, professor of ecology and agriculture at Cornell University, and Mario Giampietro, senior researcher at the National Research Institute on Food and Nutrition (INRAN), place in their 1994 study Food, Land, Population and the U.S. Economy the maximum U.S. population for a sustainable economy at 200 million. To achieve a sustainable economy and avert disaster, the United States must reduce its population by at least one-third, and world population will have to be reduced by two-thirds, says the study.[84]

The authors of this study believe that the mentioned agricultural crisis will begin to have an effect on the world after 2020, and will become critical after 2050. Geologist Dale Allen Pfeiffer claims that coming decades could see spiraling food prices without relief and massive starvation on a global level such as never experienced before.[85][86]

Wheat is humanity's third-most-produced cereal. Extant fungal infections such as Ug99[87] (a kind of stem rust) can cause 100% crop losses in most modern varieties. Little or no treatment is possible and infection spreads on the wind. Should the world's large grain-producing areas become infected, the ensuing crisis in wheat availability would lead to price spikes and shortages in other food products.[88]

Several asteroids have collided with earth in recent geological history. The Chicxulub asteroid, for example, is theorized to have caused the extinction of the non-avian dinosaurs 66 million years ago at the end of the Cretaceous. No sufficiently large asteroid currently exists in an Earth-crossing orbit; however, a comet of sufficient size to cause human extinction could impact the Earth, though the annual probability may be less than 108.[89] Geoscientist Brian Toon estimates that a 60-mile meteorite would be large enough to "incinerate everybody".[90] Asteroids with around a 1km diameter have impacted the Earth on average once every 500,000 years; these are probably too small to pose an extinction risk, but might kill billions of people.[89][91] Larger asteroids are less common. Small near-Earth asteroids are regularly observed. As of 2013, Spaceguard estimates it has identified 95% of all NEOs over 1km in size.[92]

In 1.4 million years, the star Gliese 710 is expected to start causing an increase in the number of meteoroids in the vicinity of Earth when it passes within 1.1 light-years of the Sun, perturbing the Oort cloud. Dynamic models by Garca-Snchez predict a 5% increase in the rate of impact.[93] Objects perturbed from the Oort cloud take millions of years to reach the inner Solar System.

Extraterrestrial life could invade Earth[94] either to exterminate and supplant human life, enslave it under a colonial system, steal the planet's resources, or destroy the planet altogether.

Although evidence of alien life has never been documented, scientists such as Carl Sagan have postulated that the existence of extraterrestrial life is very likely. In 1969, the "Extra-Terrestrial Exposure Law" was added to the United States Code of Federal Regulations (Title 14, Section 1211) in response to the possibility of biological contamination resulting from the U.S. Apollo Space Program. It was removed in 1991.[95] Scientists consider such a scenario technically possible, but unlikely.[96]

An article in The New York Times discussed the possible threats for humanity of intentionally sending messages aimed at extraterrestrial life into the cosmos in the context of the SETI efforts. Several renowned public figures such as Stephen Hawking and Elon Musk have argued against sending such messages on the grounds that extraterrestrial civilizations with technology are probably far more advanced than humanity and could pose an existential threat to humanity.[97]

Climate change refers to a lasting change in the Earth's climate. The climate has ranged from ice ages to warmer periods when palm trees grew in Antarctica. It has been hypothesized that there was also a period called "snowball Earth" when all the oceans were covered in a layer of ice. These global climatic changes occurred slowly, prior to the rise of human civilization about 10 thousand years ago near the end of the last Major Ice Age when the climate became more stable.[citation needed] However, abrupt climate change on the decade time scale has occurred regionally.[citation needed] Since civilization originated during a period of stable climate, a natural variation into a new climate regime (colder or hotter) could pose a threat to civilization.[citation needed]

In the history of the Earth, many ice ages are known to have occurred.[citation needed] More ice ages will be possible at an interval of 40,000100,000 years.[citation needed] An ice age would have a serious impact on civilization because vast areas of land (mainly in North America, Europe, and Asia) could become uninhabitable. It would still be possible to live in the tropical regions, but with possible loss of humidity and water.[citation needed] Currently, the world is existing in an interglacial period within a much older glacial event.[citation needed] The last glacial expansion ended about 10,000 years ago, and all civilizations evolved later than this. Scientists do not predict that a natural ice age will occur anytime soon.[citation needed]

A number of astronomical threats have been identified. Massive objects, e.g. a star, large planet or black hole, could be catastrophic if a close encounter occurred in the Solar System. In April 2008, it was announced that two simulations of long-term planetary movement, one at the Paris Observatory and the other at the University of California, Santa Cruz, indicate a 1% chance that Mercury's orbit could be made unstable by Jupiter's gravitational pull sometime during the lifespan of the Sun. Were this to happen, the simulations suggest a collision with Earth could be one of four possible outcomes (the others being Mercury colliding with the Sun, colliding with Venus, or being ejected from the Solar System altogether). If Mercury were to collide with Earth, all life on Earth could be obliterated entirely: an asteroid 15km wide is believed to have caused the extinction of the non-avian dinosaurs, whereas Mercury is 4,879km in diameter.[98]

Another cosmic threat is a gamma-ray burst, typically produced by a supernova when a star collapses inward on itself and then "bounces" outward in a massive explosion. Under certain circumstances, these events are thought to produce massive bursts of gamma radiation emanating outward from the axis of rotation of the star. If such an event were to occur oriented towards the Earth, the massive amounts of gamma radiation could significantly affect the Earth's atmosphere and pose an existential threat to all life. Such a gamma-ray burst may have been the cause of the OrdovicianSilurian extinction events. Neither this scenario nor the destabilization of Mercury's orbit are likely in the foreseeable future.[99]

If the Solar System were to pass through a dark nebula, a cloud of cosmic dust, severe global climate change would occur.[100]

A powerful solar flare or solar superstorm, which is a drastic and unusual decrease or increase in the Sun's power output, could have severe consequences for life on Earth.

If our universe lies within a false vacuum, a bubble of lower-energy vacuum could come to exist by chance or otherwise in our universe, and catalyze the conversion of our universe to a lower energy state in a volume expanding at nearly the speed of light, destroying all that we know without forewarning.[101][further explanation needed] Such an occurrence is called vacuum decay.

The magnetic poles of the Earth shifted many times in geologic history. The duration of such a shift is still debated. Theories exist that during such times, the Earth's magnetic field would be substantially weakened, threatening civilization by allowing radiation from the Sun, especially solar wind, solar flares or cosmic radiation, to reach the surface. These theories have been somewhat discredited, as statistical analysis shows no evidence for a correlation between past reversals and past extinctions.[102][103]

Numerous historical examples of pandemics[104] had a devastating effect on a large number of people. The present, unprecedented scale and speed of human movement make it more difficult than ever to contain an epidemic through local quarantines. A global pandemic has become a realistic threat to human civilization.

Naturally evolving pathogens will ultimately develop an upper limit to their virulence.[105] Pathogens with the highest virulence, quickly killing their hosts reduce their chances of spread the infection to new hosts or carriers.[106] This simple model predicts that - if virulence and transmission are not genetically linked - pathogens will evolve towards low virulence and rapid transmission. However, this is not necessarily a safeguard against a global catastrophe, for the following reasons:

1. The fitness advantage of limited virulence is primarily a function of a limited number of hosts. Any pathogen with a high virulence, high transmission rate and long incubation time may have already caused a catastrophic pandemic before ultimately virulence is limited through natural selection. 2. In models where virulence level and rate of transmission are related, high levels of virulence can evolve.[107] Virulence is instead limited by the existence of complex populations of hosts with different susceptibilities to infection, or by some hosts being geographically isolated.[105] The size of the host population and competition between different strains of pathogens can also alter virulence.[108] 3. A pathogen that infects humans as a secondary host and primarily infects another species (a zoonosis) has no constraints on its virulence in people, since the accidental secondary infections do not affect its evolution.[109]

Naturally evolving organisms, like the products of biotechnology, can disrupt essential ecosystem functions.

An example of a pathogen able to threaten global food security is the wheat rust Ug99.

Other examples are neobiota (invasive species), i.e. organisms that become disruptive to ecosystems once transportedoften as a result of human activityto a new geographical region. Normally the risk is a local disruption. If it becomes coupled with serious crop failures and a global famine it may, however, pose a global catastrophic risk.

A remote possibility is a megatsunami. It has been suggested that a megatsunami caused by the collapse of a volcanic island could, for example, destroy the entire East Coast of the United States, but such predictions are based on incorrect assumptions and the likelihood of this happening has been greatly exaggerated in the media.[110] While none of these scenarios are likely to destroy humanity completely, they could regionally threaten civilization. There have been two recent high-fatality tsunamisafter the 2011 Thoku earthquake and the 2004 Indian Ocean earthquake. A megatsunami could have astronomical origins as well, such as an asteroid impact in an ocean.[111]

A geological event such as massive flood basalt, volcanism, or the eruption of a supervolcano[112] could lead to a so-called volcanic winter, similar to a nuclear winter. One such event, the Toba eruption,[113] occurred in Indonesia about 71,500 years ago. According to the Toba catastrophe theory,[114] the event may have reduced human populations to only a few tens of thousands of individuals. Yellowstone Caldera is another such supervolcano, having undergone 142 or more caldera-forming eruptions in the past 17 million years.[115] A massive volcano eruption would eject extraordinary volumes of volcanic dust, toxic and greenhouse gases into the atmosphere with serious effects on global climate (towards extreme global cooling: volcanic winter if short-term, and ice age if long-term) or global warming (if greenhouse gases were to prevail).

When the supervolcano at Yellowstone last erupted 640,000 years ago, the thinnest layers of the ash ejected from the caldera spread over most of the United States west of the Mississippi River and part of northeastern Mexico. The magma covered much of what is now Yellowstone National Park and extended beyond, covering much of the ground from Yellowstone River in the east to the Idaho falls in the west, with some of the flows extending north beyond Mammoth Springs.[116]

According to a recent study, if the Yellowstone caldera erupted again as a supervolcano, an ash layer one to three millimeters thick could be deposited as far away as New York, enough to "reduce traction on roads and runways, short out electrical transformers and cause respiratory problems". There would be centimeters of thickness over much of the U.S. Midwest, enough to disrupt crops and livestock, especially if it happened at a critical time in the growing season. The worst-affected city would likely be Billings, Montana, population 109,000, which the model predicted would be covered with ash estimated as 1.03 to 1.8 meters thick.[117]

The main long-term effect is through global climate change, which reduces the temperature globally by about 515 degrees C for a decade, together with the direct effects of the deposits of ash on their crops. A large supervolcano like Toba would deposit one or two meters thickness of ash over an area of several million square kilometers.(1000 cubic kilometers is equivalent to a one-meter thickness of ash spread over a million square kilometers). If that happened in some densely populated agricultural area, such as India, it could destroy one or two seasons of crops for two billion people.[118]

However, Yellowstone shows no signs of a supereruption at present, and it is not certain that a future supereruption will occur there.[119][120]

Research published in 2011 finds evidence that massive volcanic eruptions caused massive coal combustion, supporting models for significant generation of greenhouse gases. Researchers have suggested that massive volcanic eruptions through coal beds in Siberia would generate significant greenhouse gases and cause a runaway greenhouse effect.[121] Massive eruptions can also throw enough pyroclastic debris and other material into the atmosphere to partially block out the sun and cause a volcanic winter, as happened on a smaller scale in 1816 following the eruption of Mount Tambora, the so-called Year Without a Summer. Such an eruption might cause the immediate deaths of millions of people several hundred miles from the eruption, and perhaps billions of deaths[122] worldwide, due to the failure of the monsoon[citation needed], resulting in major crop failures causing starvation on a profound scale.[122]

A much more speculative concept is the verneshot: a hypothetical volcanic eruption caused by the buildup of gas deep underneath a craton. Such an event may be forceful enough to launch an extreme amount of material from the crust and mantle into a sub-orbital trajectory.

Planetary management and respecting planetary boundaries have been proposed as approaches to preventing ecological catastrophes. Within the scope of these approaches, the field of geoengineering encompasses the deliberate large-scale engineering and manipulation of the planetary environment to combat or counteract anthropogenic changes in atmospheric chemistry. Space colonization is a proposed alternative to improve the odds of surviving an extinction scenario.[123] Solutions of this scope may require megascale engineering. Food storage has been proposed globally, but the monetary cost would be high. Furthermore, it would likely contribute to the current millions of deaths per year due to malnutrition.[citation needed]

Some survivalists stock survival retreats with multiple-year food supplies.

The Svalbard Global Seed Vault is buried 400 feet (120m) inside a mountain on an island in the Arctic. It is designed to hold 2.5 billion seeds from more than 100 countries as a precaution to preserve the world's crops. The surrounding rock is 6C (21F) (as of 2015) but the vault is kept at 18C (0F) by refrigerators powered by locally sourced coal.[124][125]

More speculatively, if society continues to function and if the biosphere remains habitable, calorie needs for the present human population might in theory be met during an extended absence of sunlight, given sufficient advance planning. Conjectured solutions include growing mushrooms on the dead plant biomass left in the wake of the catastrophe, converting cellulose to sugar, or feeding natural gas to methane-digesting bacteria.[126][127]

Insufficient global governance creates risks in the social and political domain, but the governance mechanisms develop more slowly than technological and social change. There are concerns from governments, the private sector, as well as the general public about the lack of governance mechanisms to efficiently deal with risks, negotiate and adjudicate between diverse and conflicting interests. This is further underlined by an understanding of the interconnectedness of global systemic risks.[128]

The Bulletin of the Atomic Scientists (est. 1945) is one of the oldest global risk organizations, founded after the public became alarmed by the potential of atomic warfare in the aftermath of WWII. It studies risks associated with nuclear war and energy and famously maintains the Doomsday Clock established in 1947. The Foresight Institute (est. 1986) examines the risks of nanotechnology and its benefits. It was one of the earliest organizations to study the unintended consequences of otherwise harmless technology gone haywire at a global scale. It was founded by K. Eric Drexler who postulated "grey goo".[129][130]

Beginning after 2000, a growing number of scientists, philosophers and tech billionaires created organizations devoted to studying global risks both inside and outside of academia.[131]

Independent non-governmental organizations (NGOs) include the Machine Intelligence Research Institute (est. 2000) which aims to reduce the risk of a catastrophe caused by artificial intelligence and the Singularity.[132] The top donors include Peter Thiel and Jed McCaleb.[133] The Lifeboat Foundation (est. 2009) funds research into preventing a technological catastrophe.[134] Most of the research money funds projects at universities.[135] The Global Catastrophic Risk Institute (est. 2011) is a think tank for all things catastrophic risk. It is funded by the NGO Social and Environmental Entrepreneurs. The Global Challenges Foundation (est. 2012), based in Stockholm and founded by Laszlo Szombatfalvy, releases a yearly report on the state of global risks.[14][15] The Future of Life Institute (est. 2014) aims to support research and initiatives for safeguarding life considering new technologies and challenges facing humanity.[136] Elon Musk is one of its biggest donors.[137] The Nuclear Threat Initiative seeks to reduce global threats from nuclear, biological and chemical threats, and containment of damage after an event.[138] It maintains a nuclear material security index.[139]

University-based organizations include the Future of Humanity Institute (est. 2005) which researches the questions of humanity's long-term future, particularly existential risk. It was founded by Nick Bostrom and is based at Oxford University. The Centre for the Study of Existential Risk (est. 2012) is a Cambridge-based organization which studies four major technological risks: artificial intelligence, biotechnology, global warming and warfare. All are man-made risks, as Huw Price explained to the AFP news agency, "It seems a reasonable prediction that some time in this or the next century intelligence will escape from the constraints of biology". He added that when this happens "we're no longer the smartest things around," and will risk being at the mercy of "machines that are not malicious, but machines whose interests don't include us."[140] Stephen Hawking was an acting adviser. The Millennium Alliance for Humanity and the Biosphere is a Stanford University-based organization focusing on many issues related to global catastrophe by bringing together members of academic in the humanities.[141][142] It was founded by Paul Ehrlich among others.[143] Stanford University also has the Center for International Security and Cooperation focusing on political cooperation to reduce global catastrophic risk.[144]

Other risk assessment groups are based in or are part of governmental organizations. The World Health Organization (WHO) includes a division called the Global Alert and Response (GAR) which monitors and responds to global epidemic crisis.[145] GAR helps member states with training and coordination of response to epidemics.[146] The United States Agency for International Development (USAID) has its Emerging Pandemic Threats Program which aims to prevent and contain naturally generated pandemics at their source.[147] The Lawrence Livermore National Laboratory has a division called the Global Security Principal Directorate which researches on behalf of the government issues such as bio-security, counter-terrorism, etc.[148]

Read this article:
Global catastrophic risk - Wikipedia

Opinion: Three must-own cancer stocks for your biotechnology portfolio – MarketWatch

June should be national cancer month.

Each year around this time, oncology groups and Wall Street brokerages hold a rash of conferences where researchers reveal the latest, greatest potential cancer cures.

This year has been no exception. Above all, we learned about remarkable advances in two exciting cancer therapies and three great companies that will benefit.

Heres more detail. (Ive kept the technical language to a minimum.)

Tumors are smart. They know how to trick the immune system into missing them. But scientists are wising up to their tricks. In one evasive strategy, tumors release an enzyme that renders them invisible. If you block the enzyme, your immune system can find tumors and destroy them with the help from cancer drugs. This is the key to an early-stage cancer weapon you should invest in, known as IDO inhibitors.

IDO stands for Indoleamine 2,3-dioxygenase, an enzyme released by tumors to blind the bodys immune system. IDO is a strange drug target, because IDO inhibition by itself has no noticeable anti-cancer effect, says Tanguy Seiwert, a cancer-therapy researcher and medical doctor who teaches at the University of Chicago. Suppressing IDO, however, makes tumors vulnerable.

The best pure play in IDO inhibitors is a company whose shares I own, and have suggested since December 2011 in my stock newsletter, Brush Up on Stocks. Were up 750% in this company since 2011 ($14 to $120). But I think this stock is still a hold because there are bigger gains ahead.

Incyte Corp. INCY, +3.58% just released excellent data on its IDO inhibitor, called epacadostat, at the American Society of Clinical Oncology (ASCO) conference. In combination with cancer therapies from Merck & Co. MRK, +1.13% and Bristol-Myers Squibb Co. BMY, +1.40% it showed excellent results against several kinds of cancer.

It looks really good. I think this was a coming-out party for IDO inhibitors, says Seiwert. Besides effectiveness, one of the main positives is that epacadostat is safe. This means it can be readily used to assist many other cancer drugs. You can add it to a ton of things because the cost is low, in terms of toxicity.

Incyte is an ideal biotech company for investors because it is self-funding. It has a very profitable drug called Jakafi, for a rare blood disorder, which supports research on new drugs like the IDO inhibitor. So investors dodge dilutive financings.

So why hasnt Incytes stock shot up? Investors have three main worries. But they look like false fears.

One bit of fake news circulating is that Incyte showed success, in part, only because it omitted patients from some results, which drove up the percentage of success stories. But this is a dubious critique for two reasons. Even if you included the three patients left out, it would only lower the success rate by a few percentage points, notes J.P. Morgan analyst Cory Kasimov. Second, Incyte offered several separate data sets showing success in many types of cancer, but the omission only affected one subgroup, says Seiwert. I think this was way overblown.

The next fear: Competitor NewLink Genetics Corp. NLNK, +3.27% recently announced Roche AG RHHBY, +0.21% handed back development rights to its IDO, following lousy results in a Roche study. Some investors take this as a sign that IDO is malarkey. But William Blair analyst Katherine Xu thinks this is bullish for Incyte, since it signals a competitor may be gone. NewLinks IDO may have fared poorly because it works differently than Incytes IDO, or because Roche used an extremely sick patient population. Neither scenario reflects poorly on Incyte.

The third knock on Incyte is the one to watch. While Seiwert is impressed with Incytes IDO results, he points out the Phase II results are early-stage, and longer-term studies are needed to learn more about patient survival. Those studies are in the works. Incyte has nine Phase III studies planned with Merck and Bristol-Myers Squibb, says Xu. The outcomes here are key, since about $50 worth of the current $120 Incyte stock price is linked to IDO.

In another key advance in cancer therapy in the past two years, doctors have learned how to extract a patients blood and genetically tweak white blood cells so they override evasive tactics used by tumors.

Then the cells are reproduced in a lab to expand the supply, and put back in the patients body so they can move in for the kill. Hopefully, the cells then continue to proliferate and thrive and stay on hand to fight any more cancer that comes along.

Known as chimeric antigen receptor T-cell therapy (CAR-T), this approach has produced remarkable results against blood cancers in patients who otherwise had almost no hope of survival. CAR-T works by unblocking cancer cell receptors normally sought out by the immune system.

This is one of the most exciting therapies in immunotherapy, said Jae Park, a Memorial Sloan Kettering Cancer Center cancer researcher and medical doctor, at the Jefferies 2017 Global Healthcare Conference in early June.

Probably the best pure play here is Kite Pharma Inc. KITE, +1.64% At the Jefferies conference, Kite CEO Arie Belldegrun showed images of a patients body riddled with tumors, which disappeared about a month after treatment began. The patient showed no sign of the disease a year later.

Kite has a product coming on the market by the end of this year, and probably many more on the way, says Brad Loncar, the cancer research expert behind the Loncar Cancer Immunotherapy CNCR, +2.93% exchange traded fund. This is pretty good progress for a therapy that was considered science fiction two years ago.

I suggested Kite in my stock letter at around $71 on May 17, and I think its still a hold even though it has already risen to $87, because this promises to be a blockbuster therapy. At the time, insiders were big buyers as the stock sold off on news of the death of a patient in one of its studies.

That unfortunate death highlights one of the key risks here. CAR-T patients have died because the therapy can cause brain swelling. Doctors are getting better at staving off adverse side effects, says Park. But they still dont fully understand what causes them, which should raise a yellow flag for investors.

Kite also faces competition from other companies developing CAR-T, including power players like Novartis AG NVS, +0.75% Pfizer Inc. PFE, +0.76% Johnson & Johnson JNJ, -0.21% and GlaxoSmithKline PLC GSK, -0.09% as well as Juno Therapeutics Inc. JUNO, +3.91% Cellectis SA CLLS, +0.00% Adaptimmune Therapeutics PLC ADAP, -0.44% and two privately held companies called Poseida Therapeutics and Nanjing Legend Biotech.

Any of these efforts may pan out nicely, but my pick as a third CAR-T play is bluebird bio BLUE, +3.59% which is partnering with Celgene Corp. CELG, +2.29% Bluebird just announced really impressive results for its CAR-T candidate called bb2121. In early studies, just released at ASCO, this therapy produced an overall response rate of 90% to 100% among hospice-type patients whose cancer was so bad that seven different attempts to cure them, on average, had failed.

To generate efficacy data on this level with an overall very tolerable safety profile is highly impressive, says Kasimov, at J.P. Morgan. With more key updates to come in 2017, we would continue to add to positions in bluebird bio.

At the time of publication, Michael Brush held INCY. Brush has suggested INCY and KITE in his stock newsletter Brush Up on Stocks. Brush is a Manhattan-based financial writer who has covered business for the New York Times and The Economist group, and he attended Columbia Business School in the Knight-Bagehot program.

Go here to read the rest:
Opinion: Three must-own cancer stocks for your biotechnology portfolio - MarketWatch

NICreL Seeks FG’s Support For NABDA To Boost Biotechnology … – Leadership Newspapers

By Michael Oche, Abuja

The New Initiative for Credible Leadership, a leading research and development based Civil Society Organization in Nigeria has hailed the National Biotechnology Development Agency (NABDA) under the leadership of Professor Mrs. Lucy Ogbadu for her innovations in biotechnology and genetic engineering in the country.

NABDA is an organization aimed at promoting, coordinating, and setting research and development priority in biotechnology for Nigeria.

NICreL noted the ongoing economic quandary in Nigeria as a result of fall in oil prices calls for all stakeholders to put on their thinking cap for the country to move away from its over dependency and focus on other sectors, particularly agriculture which was the mainstream of the countrys gross national earnings was booming before the advent crude oil.

Addressing newsmen on the activities of Nigerias research institutions in Abuja, Reverend Steven Onwu, Executive Secretary of the Centre, averred that NABDA within the last two years has continued to work assiduously hard under its mandate to put the nation at par with global realities through its various innovations, scientific breakthroughs in the field of genetics and intellectual acumen to move the country forward.

Onwu noted that Professor Ogbadu is demonstrating to Nigerians through her sterling leadership anchored on accountability, probity and transparency that our journey to the promised land is not a mirage if we put all hands on deck and the country first in all our dealings.

His words, The organization is patriotically driving the change agenda by blazing the trail in this uncommon field and the agency deserves a better funding support to do more.

No country in the world is as naturally endowed as Nigeria in terms of 21st century resources that are scattered across the various locations in the country and would require the needed intellectual drivers to achieve that amount of greatness which is commensurate with our resources.

The NICreL executive, while calling on the Nigerian Government to support the Ogbadu-led NABDA, noted that the agency needed more encouragement to continue to promote biotechnology activities that positively respond to national aspirations on food security, job/wealth creation, affordable healthcare delivery and sustainable environment.

Original post:
NICreL Seeks FG's Support For NABDA To Boost Biotechnology ... - Leadership Newspapers

Advancements in Biotechnology to Boost Uptake of Ampoules Worldwide – TMR Research Blog (press release) (blog)

San Francisco, California, June 20, 2017: The flourishing growth of the pharmaceutical packaging industry worldwide is the primary growth stimulant of the global ampoules market worldwide. The advent of novel injectable therapies due to research and advancements in the field of biotechnology is also augmenting the market. A report by TMR Research, titled Ampoules Market Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 20172025, extensively covers all the vital parameters of the market, including vendor landscape and regional segmentation.

Stringent government regulatory framework and industry standards for pharmaceutical packaging are stoking the growth of the global ampoules market. Strict standards and regulations are compelling manufacturers to elevate their packaging practices such that there is no compromise in terms of efficacy and quality of drugs. The spiraling demand for safer transportation of reactive liquids is also providing a significant push to the global market. Besides this, the increasing usage of ampoules in the food and beverage industry is working in favor of the global market.

On the flip side, dumping of ampoules still remains a major concern among governments and pharmaceutical organizations worldwide. Plastics and glasses are non-degradable and therefore, have impact the environment negatively. The rising environmental concerns are, thus, limiting the market from realizing its utmost potential. Nevertheless, the rising incorporation of sustainable materials such as biodegradable plastics or green plastics in the manufacturing of ampoules is likely to provide a significant momentum to the market in the near future. Furthermore, market participants are increasingly focusing towards product extensions and technological innovations, which is expected to bode well for the growth of the market.

On the basis of geography, the market can be fragmented into Europe, Latin America, North America, Asia Pacific, and the Middle East and Africa. North America and Europe are anticipated to account for a substantial cumulative share in the global ampoules market. Rapid advancements in the biotechnology in these regions are augmenting the applications of ampoules. While developed countries will be major revenue contributors, developing regions will emerge as a strong contender during the review period. Asia Pacific is estimated to witness healthy growth, owing to the robust growth of the pharmaceutical and packaging industry.

Some of the key companies operating in the global market for ampoules are Truking Technology Limited, Bausch-Stroebel, Hunan China Sun Pharmaceutical Machinery Co. Ltd., Shanghai Far-East Pharmaceutical Machinery CO. Ltd., Nipro Glass, SCHOTT, Gujarat Fabricators, Essco Glass, Kishore Group, Ciron Group of Companies, James Alexander Corporation, Kapoor Glass Pvt. Ltd, A. H. Industries, Global Pharmatech, Claris Lifesciences Ltd., and Lifespan Biotech Private Ltd.

Like Loading...

See the article here:
Advancements in Biotechnology to Boost Uptake of Ampoules Worldwide - TMR Research Blog (press release) (blog)

Biotechnology could spur Africa’s industrialisation – Southern Times Africa

Sifelani Tsiko recently in Lilongwe, Malawi

An industrial development strategy could be built on the back of Africas agricultural sector underpinned by the adoption of new and emerging technologies such as biotechnology to support improved yields, value addition and services that feed into the whole agro-processing value chain, a top Common Market for Eastern and Southern Africa (COMESA) official says.

Getachew Belay, a senior biotechnology policy advisor told Zimpapers Syndication recently on the sidelines of a communication training workshop for journalists on biotechnology and biosafety, that the adoption of genetically modified cotton developed using a bacterium Bacillus thuringiensis (Bt) which naturally produces a chemical harmful only to a small fraction of insects such as the bollworm, could increase yields and enhance competitiveness.

He says cotton farmers in Africa suffer huge losses due to pest problems.

The most destructive of pests is the African bollworm (Helicoverpa armigera), which can cause severe losses of up to 100 percent like we saw on some cotton fields in Salima here in Malawi, the Comesa biotech policy advisor says.

In unprotected fields pest damage can be very severe and when you look at Bt cotton crop on trial you can see hope that its possible for African farmers to increase their yields and competitiveness of their crop on the market.

Using Bt cotton developed using bacterium Bacillus thuringiensis, which naturally produces a chemical harmful only to a small fraction of insects such as the bollworm, experts say reduction in pest infestations can increase yields and improve the livelihoods of cotton growers.

The Bt toxin is inserted into cotton, causing cotton, called Bt cotton, to produce this natural insecticide in its tissues.

Biotechnology experts argue that cotton farmers in Zimbabwe, Malawi and most other African countries, can effectively reduce input costs and control damage from bollworms and other insects that frequently damage cotton by adopting Bt cotton.

For several decades, has lagged behind in terms of the industrial dynamism required to boost farmer earnings, employment, economic growth and competitiveness on the global market.

But in recent years, there is a growing realisation of the importance of industrialisation.

In 2016, the UNs Economic Commission for Africa (UNECA) published a major report on industrialization in Africa where it asserts that structural transformation in Africas economies remains the highest priority and industrialization is the top strategy for achieving it in practice.

And, Belay says, biotechnology is one of the major tools for achieving industrialisation.

Im convinced that biotechnology has many opportunities to drive Africas industrialisation, he says.

We have Bt cotton, Bt maize and soya and biotechnology can enhance the competitiveness of our crops and agricultural products especially when it comes to value addition and beneficiation as it was stipulated in our African industrialisation agenda.

Already we are seeing the benefits of adopting biotech crops in South Africa. Livestock feed sectors in Zambia and even Zimbabwe cannot compete with SAs GM stock feed which is produced cheaply. We need to adopt this new technology to cut costs.

Europe relies heavily on GM soya for its livestock feed industry and this has enhanced its competitiveness.

Africa has a low uptake of biotech food crops due to lack of awareness and stiff resistance, scientists say.

International Service for the Acquisition of Agri-Biotech Applications (ISAAA) AfriCenter director Margaret Karembu told journalists at the workshop that adoption of agricultural biotechnology has lagged behind compared to the rapid rates seen in the medical and health sectors.

Where are we as Africans? This is the question, we need to think seriously about the good work (on agricultural biotechnology) going on in our labs, she said. What is our place in the global biotechnology space? We need reclaim it and improve the livelihoods of our farmers across the continent.

Karembu said lack of awareness and a constrained regulatory environment had also slowed down the uptake of agricultural biotechnology.

Lack of awareness of the benefits and the regulatory framework has affected the tide towards the adoption of biotechnology. The victim mentality has been largely to blame for this.

We think of ourselves as victims of the technology. The fact is that our public institutions and universities have been doing research on biotech crops for years and this has not moved to the commercialization stage, she says. She says Africa needs to diffuse myths and misconceptions around GMO crops.

The media has a big role to play in clearing some of the misconceptions about biotechnology and GMOs, the ISAAA director says.

When media demonises the science, it becomes difficult to correct the mistakes. There is a lot of unfamiliarity with the technology and having fixed mind sets will not help our struggling farmers.

The farmers you saw in Salima are poor and they are struggling. Why should we block them from accessing the Bt cotton varieties that can significantly boost their yields and income? Farming should not be for leisure, its a business and it should be there to improve the quality of livelihoods of the farmers.

Biotechnology is one of the tools we can use to first of all improve crop yields and secondly to support Africas industrialisation goals for value addition and beneficiation.

Karembu urged the media to encourage dialogue and to correct misinformation.

The information we generate should be guided by credible scientific evidence and not unverified Google information, she says. If you have a headache people just Google and Google has become the answer. The world is polluted by a lot of unsubstantiated facts. We need to change the narrative and challenge the myth that Africa enjoys being poor the romanticisation of poverty.

Stringent and expensive regulatory process in Africa has slowed down uptake of biotechnology crops.

Biotech experts say the regulatory process is burdensome and makes everything unpredictable while in some African countries there is fear of change and challenging of the status quo when it comes to biotechnology.

According to ISAAA, the production of biotech crops increased 110-fold from 1996 with countries now growing the crops on 2,1 billion hectares worldwide.

The global value of the biotech seed market alone was US$15,8 billion in 2016. A total of 26 countries, 19 developing and 7 industrial grew biotech crops.

By 2016, at least four countries in Africa had in the past placed a GM crop on the market. These included Egypt, South Africa, Burkina Faso and Sudan.

But due to some temporary setback in Burkina Faso and Egypt, only South Africa and Sudan planted biotech crops on 2,8 million hectares

South Africa is one of the top 10 countries planting more than one million hectares in 2016 and continued to lead the adoption of biotech crops on the African continent.

Kenya, Malawi and Nigeria have transitioned from research to granting environmental release approvals while six others Burkina Faso, Ethiopia, Ghana, Nigeria, Swaziland and Uganda made significant progress towards completion of multi-location trials in readiness for considering commercial approval, ISAAA reported.

But the road to the adoption of Bt cotton technologies in Africa still faces stiff resistance.

Supporters of GM crops have to grapple with vocal anti-GMO activists, limited capacity to deal with the processing of GM research applications, bureaucratic delays in approving field trials, mistrust and resistance from key decision makers in Government and limited public awareness of the issues surrounding research and development of GM crops.

In addition, they have to contend with issues related to disease resistance, bottlenecks encountered when co-ordinating with other line ministries, trade-related restrictions, biosafety regulation and the overwhelming influence of multinational companies, Governments and their sidekicks NGOs. And, despite the threats, biotechnology experts say benefits from the biotech agro-linked industrial development outweigh the threats.

SADC drew up its Industrialisation Strategy and Roadmap which seeks to speed up industrialisation by strengthening the comparative and competitive advantages of the economies of the region.

The strategy which covers the period 2015 2063 is anchored on three pillars industrialisation, competitiveness and regional industrialisation.

The whole industrialisation agenda aims to help SADC member states to achieve high levels of economic growth, competitiveness, incomes and employment.

To access the funds, SADC countries have set up committees made up of government and private sector players to identify priority areas for funding.

At regional level, three areas have been prioritised, namely agro processing, mining and downstream processing.

For all this, biotechnology could be a useful tool to drive the regions industrialisation agenda, Belay says.

Its not a silver bullet, but its one of the many tools we can use to drive the continents industrialisation strategy. Agriculture is fundamental to Comesa member states in terms of improving food and nutrition security, increasing rural income, employment and contributions to GDP and expert earnings.

We need to explore ways of enhancing the use of biotechnology to drive industrialisation and improved livelihoods for farmers in Africa.

Analysts say Africa badly needs increased investment in infrastructure of all kinds reliable clean energy and water systems, medical clinics, technical colleges, railways, roads, bridges, fiber optic networks, and factories of many kinds.

Industrialisation can benefit the expansion of intra-African trade by supporting a more diversified export economy, wrote an economic analyst.

In particular, the development of rural and food processing industries could help to lift significant numbers from poverty. But, to facilitate trade in goods and services, it is essential to reduce distribution costs by improving and expanding road, rail and other communication infrastructure. -Zimpapers Syndication

Continued here:
Biotechnology could spur Africa's industrialisation - Southern Times Africa

On eve of biotech’s big convention, BIO boss talks drug prices, ‘biosimilars’ and Trump BioFlash podcast – San Francisco Business Times

On eve of biotech's big convention, BIO boss talks drug prices, 'biosimilars' and Trump BioFlash podcast
San Francisco Business Times
As 16,000 biotech executives land in San Diego this week for the annual Biotechnology Innovation Organization conference, old issues continue to simmer while new ones emerge with the rise of President Donald Trump. The BIO convention, which runs ...

Read more from the original source:
On eve of biotech's big convention, BIO boss talks drug prices, 'biosimilars' and Trump BioFlash podcast - San Francisco Business Times

Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19 – Yahoo Finance

SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc.(VIR) today announced that it has signed a letter of intent with Biogen Inc. (BIIB) for the development and clinical manufacturing of human monoclonal antibodies for the potential treatment of COVID-19, the disease caused by the SARS-CoV-2 virus. Because of the urgency of the situation, the companies have begun work while a Clinical Development and Manufacturing Agreement is being negotiated. Subject to the completion of a definitive agreement, Biogen would continue cell line development, process development, and clinical manufacturing activities in order to advance the development of Virs proprietary antibodies.

These exceptional circumstances presented by the threat of COVID-19 require that we work with great urgency in the interest of the public good, said George Scangos, Ph.D., CEO, Vir. Biogen is one of the global leaders in cell line and process development for advanced biologics; tapping into their capabilities will provide us with a U.S. base for supply and manufacture of antibody therapies.

Vir has identified a number of monoclonal antibodies that bind to SARS-CoV-2, which were isolated from individuals who had survived a SARS (Severe Acute Respiratory Syndrome) infection. The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

About Virs Antibody Platform

Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. This platform has been used to identify and develop antibodies for pathogens including Ebola (mAb114, currently in use in theDemocratic Republic of Congo), hepatitis B virus, influenza A, malaria, and others.

AboutVir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus, and tuberculosis. For more information, please visit http://www.vir.bio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend, potential and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the companys efforts to neutralize the SARS-CoV-2 virus and identify additional potential therapies for SARS-CoV-2, its ability to address the emerging public health epidemic, and its ability to enter into an agreement with Biogen, and its ability to secure a U.S. base for supply and manufacture of antibody therapies. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in neutralizing SARS-CoV-2, difficulty in reaching a definitive agreement with Biogen, challenges of collaborating with other companies or government agencies, and challenges in accessing manufacturing capacity. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with theU.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Story continues

Contact:Vir Biotechnology, Inc.Investors Neera Ravindran, MDHead of Investor Relations & Strategic Communications nravindran@vir.bio+1-415-506-5256

Media Lindy Devereux Scient PR lindy@scientpr.com +1-646-515-5730

Read the original:
Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19 - Yahoo Finance

Is GeneReach Biotechnology Corp. (GTSM:4171) Investing Effectively In Its Business? – Simply Wall St

Today well evaluate GeneReach Biotechnology Corp. (GTSM:4171) to determine whether it could have potential as an investment idea. To be precise, well consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business.

First of all, well work out how to calculate ROCE. Second, well look at its ROCE compared to similar companies. Then well determine how its current liabilities are affecting its ROCE.

ROCE measures the return (pre-tax profit) a company generates from capital employed in its business. In general, businesses with a higher ROCE are usually better quality. Overall, it is a valuable metric that has its flaws. Renowned investment researcher Michael Mauboussin has suggested that a high ROCE can indicate that one dollar invested in the company generates value of more than one dollar.

Analysts use this formula to calculate return on capital employed:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) (Total Assets Current Liabilities)

Or for GeneReach Biotechnology:

0.11 = NT$72m (NT$713m NT$61m) (Based on the trailing twelve months to September 2019.)

Therefore, GeneReach Biotechnology has an ROCE of 11%.

View our latest analysis for GeneReach Biotechnology

One way to assess ROCE is to compare similar companies. Using our data, GeneReach Biotechnologys ROCE appears to be around the 9.5% average of the Medical Equipment industry. Regardless of where GeneReach Biotechnology sits next to its industry, its ROCE in absolute terms appears satisfactory, and this company could be worth a closer look.

GeneReach Biotechnology has an ROCE of 11%, but it didnt have an ROCE 3 years ago, since it was unprofitable. That implies the business has been improving. The image below shows how GeneReach Biotechnologys ROCE compares to its industry, and you can click it to see more detail on its past growth.

When considering this metric, keep in mind that it is backwards looking, and not necessarily predictive. ROCE can be misleading for companies in cyclical industries, with returns looking impressive during the boom times, but very weak during the busts. ROCE is only a point-in-time measure. Since the future is so important for investors, you should check out our free report on analyst forecasts for GeneReach Biotechnology.

Current liabilities are short term bills and invoices that need to be paid in 12 months or less. Due to the way the ROCE equation works, having large bills due in the near term can make it look as though a company has less capital employed, and thus a higher ROCE than usual. To counteract this, we check if a company has high current liabilities, relative to its total assets.

GeneReach Biotechnology has total assets of NT$713m and current liabilities of NT$61m. As a result, its current liabilities are equal to approximately 8.6% of its total assets. With low current liabilities, GeneReach Biotechnologys decent ROCE looks that much more respectable.

This is good to see, and while better prospects may exist, GeneReach Biotechnology seems worth researching further. GeneReach Biotechnology shapes up well under this analysis, but it is far from the only business delivering excellent numbers . You might also want to check this free collection of companies delivering excellent earnings growth.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See original here:
Is GeneReach Biotechnology Corp. (GTSM:4171) Investing Effectively In Its Business? - Simply Wall St

Global Marine Biotechnology Market 2020-2024 | Evolving Opportunities With Aker BioMarine AS and BASF SE | Technavio – Business Wire

LONDON--(BUSINESS WIRE)--The marine biotechnology market is poised to grow by USD 2.5 billion during 2020-2024, progressing at a CAGR of over 8% during the forecast period. Request free sample pages

Read the 120-page report with TOC on "Marine Biotechnology Market Analysis Report by Application (Healthcare products, Energy and environment management products, and Food and cosmetics products), Geographic segmentation (APAC, Europe, MEA, North America and South America), and the Segment Forecasts, 2020-2024."

https://www.technavio.com/report/marine-biotechnology-market-industry-analysis

The market is driven by the increase in demand for biofuel. In addition, the increasing application of seaweeds is anticipated to boost the growth of the marine biotechnology market.

The rise in demand for energy across the world is propelling the demand for fossil fuels. However, the increase in global warming, rise in prices of petroleum-based fuels, need for energy protection, and scarcity of fossil fuels is compelling economies to adopt renewable energy sources such as biomass. Biomass is derived from various forest, agriculture, and aquatic sources using the process of marine biotechnology. Biomass is used as feedstock to produce several biofuels such as biodiesel, bioethanol, biohydrogen, bio-oil, and biogas. Algal biomass is also gaining prominence as an alternative feedstock to produce biofuels. The increase in such biofuels through the application of marine biotechnology is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Marine Biotechnology Market Companies:

Aker BioMarine AS

Aker BioMarine AS offers SUPERBA KRILL, QRILL Aqua, and QRILL Pet. SUPERBA KRILL is a natural source of omega-3S, phospholipids, choline, and astaxanthin. QRILL Aqua is rich in phospholipid-bound omega-3 fatty acids, the antioxidant astaxanthin, proteins, and minerals. QRILL Pet is a natural source of omega-3 fatty acids, marine proteins, and astaxanthin.

BASF SE

BASF SE offers products through the following business units: Chemicals, Performance Products, Functional Materials & Solutions, and Agricultural Solutions. The company offers Dry n-3 DHA 11A and Lucantin Pink.

CP Kelco

CP Kelco operates under various business segments, namely Carboxymethyl Cellulose (CMC) / Cellulose Gum, Carrageenan, Citrus Fiber, Diutan Gum, and Others. The company offers GENULACTA and GENUTINE.

Cyanotech Corp.

Cyanotech Corp. offers Hawaiian Spirulina and Cyanotech BioAstin Hawaiian Astaxanthin. Hawaiian Spirulina is used in the treatment of immune system, eyes and brain, cardiovascular health, and overall cellular health. Cyanotech BioAstin Hawaiian Astaxanthin is used in the treatment of joint and tendon health, skin health, cardiovascular health, and others.

KD Pharma Group

KD Pharma Group offers products through the following business segments: KD Pharma, KD Nutra, and KD Biopharma. The company offers Omega-3 products such as ALFA gastro-resistant capsules, which is used for the treatment of familial adenomatous polyposis and ulcerative colitis.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Marine Biotechnology Market Application Outlook (Revenue, USD Billion, 2020-2024)

Marine Biotechnology Market Geographic segmentation Outlook (Revenue, USD Billion, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care Include:

Molecular Biology Enzymes, Kits, and Reagents Market Global Molecular Biology Enzymes, Kits, and Reagents Market by end user (biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and academic institutes and research organizations), and geography (Asia, Europe, North America, and ROW).

Molecular Weight Marker Market Global Molecular Weight Marker by product (DNA marker, protein marker, and RNA marker) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

See original here:
Global Marine Biotechnology Market 2020-2024 | Evolving Opportunities With Aker BioMarine AS and BASF SE | Technavio - Business Wire

The Benefit of Hands-On Experience in Biotechnology Graduate Programs – Azusa Pacific University

Biotechnology is not only an exciting career that covers a broad range of career fields engaged in advancing medical technologyits also a quickly growing job choice. In fact, according to Grand View Research, the biotechnology market is expected to reach $727.1 billion by 2025.

The skills and experience that students can gain from biotechnology graduate programs are crucial to excelling in this rapidly evolving field. But not all biotechnology graduate programs are created the samewhile its essential to master the curriculum, some lessons are better grasped through hands-on experience and training.

This is what sets Azusa Pacific Universitys M.S. in Biotechnology apart. The program focuses on internships and masters projects with pharmaceutical, biopharmaceutical, and medical device companies.

Academic laboratories are crucial and, at APU, courses are taught by industry professionals. But with the biotech industry changing continually, it can be a challenge for students to experience current technical advances unless theyre directly in the field. APUs program incorporates onsite internship experiences to ensure every program graduate is well-versed in the industry landscape.

Almost half of the top biotech companies are headquartered in California, in cities likes San Francisco and Los Angeles. APU is just 26 miles from L.A., which gives biotech students many opportunities to work alongside top professionals in the field. Students collaborate with companies like Gilead Sciences, Amgen, and Medtronic, where theyre able to observe state-of-the-art technical practices currently used in the industry. David Dyer, Ph.D., executive director of APUs M.S. in Biotechnology program, explained that this experience also allows students to understand aspects of a companys work environment, including communication, team function, leadership, and management style.

The goal is for grad students to obtain the skills needed to go from classroom to career field seamlessly.

A second reason the M.S. in Biotechnology program emphasizes in-person work with companies is that the company can get a long look at the student as a potential future hire, said Dyer. Companies can also place students on projects where they may require additional assistance.

Justin Hoang, a current biotech student, said that his internship with Grifols was a valuable learning experience. I learned how to operate new systems and software that pertained to the career I wish to pursue after graduation, he noted.

Graduates of APUs biotech program receive a head start on their rsums as well, as theyre able to list their experience with widely recognizable companies. The program prepares individuals for a variety of biotech careers, including those in epidemiology, genetic counseling, and microbiology.

APU alum Najeh Salamah enrolled in the M.S. in Biotechnology program after being away from school for a while. Salamah said, The well-rounded program sets you up for success, and you dont have to be a traditional biology/chemistry major.

Students of the program are required to complete 900 hours of onsite training, so every graduate will be adequately exposed to corporate practice and culturebut you wont be alone throughout the program. Salamah said that the programs faculty, counselors, and director are like family and work to guide their classes to have fruitful and compelling interaction. The faculty want their students to succeed and work to make everyone feel welcome.

Are you interested in becoming part of the biotech family at Azusa Pacific University and working toward your M.S. in Biotechnology? Learn more about the programs associated coursework and academic requirements.

Posted: March 10, 2020

See the original post:
The Benefit of Hands-On Experience in Biotechnology Graduate Programs - Azusa Pacific University

Latest Research Report to uncover key Factors of Biotechnology Market 2019 with high CAGR in Coming Years with Focusing Key players and Forecast to…

Crystal Market Research Offers Research Report gives a wide Information of the new and rising patterns in the Global Biotechnology Market. The report gives an evaluation of the qualities and strengths of the market alongside different elements which are expected to hinder the Industry. It likewise clarifies the elements of Biotechnology Market advertise in detail for a far comprehensive understanding.

Apply Here For the Free Sample Copy of the Report: https://www.crystalmarketresearch.com/report-sample/HC012294

Continue

The Global Biotechnology market is the expert and exact investigation of different business viewpoints, for example,major key players, key topographies, divers, restraints, openings, and difficulties. This worldwide research report has been Completely based on different market portions and sub-sections related with the Industry.

Get Discount of This Precious Report @ https://www.crystalmarketresearch.com/check-discount/HC012294

Geographically, this Biotechnology report studies Market share and growth opportunity in these key regions, covering:

Inquiry More to get further questions resolved: https://www.crystalmarketresearch.com/send-an-enquiry/HC012294

Contacts Us:

Judy | 304 South Jones Blvd, Suite 1896

Las Vegas NV 89107

United States

E-mail: sales@crystalmarketresearch.com | Ph: 888-213-4282

Go here to read the rest:
Latest Research Report to uncover key Factors of Biotechnology Market 2019 with high CAGR in Coming Years with Focusing Key players and Forecast to...

XBiotech Added to NASDAQ Biotechnology Index – PharmiWeb.com

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.

ABOUT THIRD PARTY LINKS ON OUR SITE

PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.

PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.

Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

Visit link:
XBiotech Added to NASDAQ Biotechnology Index - PharmiWeb.com

Food security experts shift focus to biotechnology – The Express Tribune

A labourer sifts wheat crop in a field. PHOTO: REUTERS

LAHORE:There is a dire need for increasing the agricultural yield to feed an increasing global population, food security experts emphasised on Saturday, highlighting biotechnology and its sub-fields as the key to increasing the productivity per acre.

Remedies derived from biotechnology could allow crop adaptation to biotic and abiotic stresses arising due to massive climate change at the global level, they said, adding technologies like genetic engineering could transform agricultural practices massively to make the sector more productive.

Food Security Policy: PARC finalises draft for cabinet review

Biotechnology is playing an important role in mitigating adverse impacts of climate change on agricultural output by reducing emission of greenhouse gases, said Professor of Biotechnology at FCC University Lahore Dr Kauser Malik.

He said the use of biofuels, for example, would help solve energy supply problems by providing renewable and cheap energy for farmers, apart from reducing the adverse impact of carbon dioxide emissions.

Carbon dioxide emissions are reduced by using traditional and genetically modified crops such as sugarcane, oilseed and rapeseed, he said, adding the need for tillage could also be reduced with the help of genetically modified crops.

We can modify plants through genetic engineering so that they absorb relatively more carbon from the atmosphere and convert it into oxygen. Soil fertility can also be increased by mixing microbes in the soil. In this context, modern environmental biotechnology has gained immense importance in coming up with innovative ways of increasing productivity, Malik said.

Experts claim that rainfall volatility, increasing drought conditions and drastic rises in temperatures all symptoms of climate change affect food production and are also responsible for pest, disease and weed outbreaks in crops.

Fast-paced climate change, experts claim, is not providing crops enough time to adjust to the changing environment, thereby stifling growth. According to an estimate, in 20 to 25 years, the world will get to a point where climatic conditions in most fertile areas will become too extreme for growing crops.

Pakistan Agriculture Research Council: Govt dept fires 500 employees

Malik said under the circumstances, increasing the area under production and improving productivity on the existing farmland were the only two choices to overcome food security challenges and adapt to changing climatic conditions.

Transgenic canola and soybean have been modified to be resistant to specific herbicides. Fungi, bacteria and virus-resistant GM cassava, potatoes, bananas and other crops are also being developed with some having already been commercialised while others are undergoing field trials, he added.

Published in The Express Tribune, August 20th, 2017.

LikeBusiness on Facebook, follow @TribuneBizon Twitter to stay informed and join in the conversation.

Original post:
Food security experts shift focus to biotechnology - The Express Tribune